Published in Medicine and Law Weekly, December 30th, 2005
These early-stage studies found Multiferon (multi-subtype, human natural alpha interferon) to be significantly more active against the virus than recombinant alpha interferon, recombinant beta interferon or ribavirin. Viragen officials believe these results suggest that Multiferon may have utility against this viral threat and is a prime candidate worthy of further evaluation in additional avian...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly